Genmab — Maj 2020
-
Go´ pointe JKY
-
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Halozyme (HALO) to $39 from $35 and keeps an Overweight rating on the shares after the company announced that the ENHANZE-based DARZALEX subcutaneous formulation, now called DARZALEX FASPRO, which is licensed to Janssen (JNJ), was approved by the FDA. Duncan tells investors in a research note that because the breadth of the approved label exceeds even his
-
Jan varslede i forbindelse med interview omkring GF. nærmere en nedjustering af dara salg pga corona
-
Så jeg serr ikke en opjustering komme uden der er lavet en ny liccensdeal med upfront betaling
-
Ikke meget ketchup i dag...;-)
-
Når sælgerne ikke kan komme ud på sygehusene, så er det i denne tid ikke let at introducere ny medicin. Der er nok en årsag til verdens mest optimistiske Jan
selv varslede nedjustering af dara salg i år -
SB det er forbudt at markedsføre endnu ikke godkendt medicin i US. Det kan koste endog særdeles store bøder. Så det tænker jeg gerne JnJ vil undgå
Lægerne skal dels have præsentert de nye data vs IV og derudover skal lægerne også undervises i brugen. Ting der bare går en hel del mere smidigt ved man reelt fysisk kan være tilstede -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind